BioPharmSignal logoBioPharmSignal

Biotech News

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026

Organogenesis (ORGO)Organogenesis2026-06-25 13:46 ESTEarnings

CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and

Open original release

Related news

ORGOOrganogenesis2026-06-25 13:46 EST

Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results

ORGOOrganogenesis2026-06-25 13:46 EST

Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ORGOOrganogenesis2026-06-25 13:46 EST

Organogenesis Applauds CMS’s Significant Step In Payment Reform

ORGOOrganogenesis2026-06-25 13:46 EST

Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance

ORGOOrganogenesis2026-06-25 13:46 EST

Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain

ORGOOrganogenesis2026-06-25 13:46 EST

Organogenesis Announces Initiation of Biologics License Application for ReNu®

ORGOOrganogenesis2026-06-25 13:46 EST

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

ORGOOrganogenesis2026-06-25 13:46 EST

Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue

ORGOOrganogenesis2026-06-25 13:46 EST

Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM

ORGOOrganogenesis2026-06-25 13:46 EST

Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®

View all latest news

Organogenesis

Organogenesis is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

ORGOOrganogenesis2026-06-26 10:42 EST

Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results

ORGOOrganogenesis2026-06-26 10:42 EST

Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ORGOOrganogenesis2026-06-26 10:42 EST

Organogenesis Applauds CMS’s Significant Step In Payment Reform

ORGOOrganogenesis2026-06-26 10:42 EST

Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance

ORGOOrganogenesis2026-06-26 10:42 EST

Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States